SLNO earnings analysis
What we found in SLNO's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Soleno Therapeutics demonstrated a strong performance in Q1 2026 with product revenue of $94.6 million, a significant increase compared to zero revenue in Q1 2025, marking a remarkable growth trajectory since the FDA approval of VYKAT XR. The company also reported a net income of $31.4 million, a turnaround from the net loss of $43.8 million in the prior year period, reflecting improved profitability and operational efficiency.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Significant Revenue Growth
- Product revenue reached $94.6 million for Q1 2026, up from $0 in Q1 2025.
- Profitability Achieved
- Net income for Q1 2026 was $31.4 million, compared to a loss of $43.8 million in Q1 2025.
- Strengthened Operating Income
- Operating income turned positive at $31.3 million for Q1 2026, up $77.0 million year-over-year.
- Cash Flow Improvement
- Net cash from operating activities was $26.0 million in Q1 2026, a significant improvement from a cash outflow of $32.8 million previously.
- Increased Cash Position
- As of March 31, 2026, cash and cash equivalents totaled $133 million, supporting operational liquidity.
- R&D Expense Reduction
- R&D expenses decreased to $11.3 million in Q1 2026, down 17% from $13.5 million in Q1 2025.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Regulatory Dependency Risk
- The pending Merger Agreement with Neurocrine could introduce uncertainties affecting business continuity.
- Litigation Risk
- The class-action lawsuit filed against the company on March 6, 2026, could lead to financial and reputational risks.
- International Expansion Delays
- The withdrawal of the MAA for VYKAT in the EU could delay potential revenue from European commercialization.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $0.84
- Operating margin
- 33.1%
What they said about what is next.
Outlook deferred to earnings press release / call.
The filing reads better than the one before it.
What came before.
- 10-K · April 30, 2026
- Soleno Therapeutics reported significant growth, achieving net revenue of $190.4 million in 2025, driven by the successful commercialization of VYKAT XR for Prader-Willi syndrome. The company has also entered a merger…
- 10-K · February 25, 2026
- Soleno transitioned to commercial-stage in 2025 after FDA approval of VYKAT XR on March 26, 2025 and began recognizing product revenue after prescriptions were delivered on April 14, 2025. Financials show a clear…
- 10-Q · August 6, 2025
- Soleno reported first commercial product revenue following FDA approval of VYKAT XR, recognizing product revenue of $32,657 (thousands) in Q2 2025 and narrowing GAAP loss to $(0.09) per share for the quarter. Revenue…
- 10-Q · August 7, 2024
- Soleno reported a Q2 net loss of $21.9M (EPS -$0.57) for the three months ended June 30, 2024, compared with a net loss of $8.5M (EPS -$0.81) in Q2 2023; the EPS beat the consensus estimate of -$0.63. Operating expenses…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing SLNO makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever